Matthew D. Galsky, MD

Matt Galsky, MD, discusses the phase 3 NIAGARA trial that led to the recent FDA approval of durvalumab in muscle-invasive bladder cancer after radical cystectomy.

Matthew Galsky, MD, discusses the future of bladder cancer research and the impact of new treatments such as immune checkpoint inhibitors and antibody-drug conjugates.

The emerging arena of checkpoint inhibitors and immunotherapy in the treatment of urothelial carcinomas is explored and discussed.

Matthew D. Galsky, MD, Professor of Medicine, Mount Sinai School of Medicine, discusses progression in patients with metastatic bladder cancer.

Metastatic urothelial cancer is a relatively chemotherapy-sensitive malignancy. With contemporary cisplatin-based combination chemotherapy regimens, objective responses are achieved in approximately 50-60% of patients and complete radiographic responses are achieved in approximately 10-20% of patients.

Matthew D. Galsky, MD, from The Mount Sinai Hospital, discusses an analysis of the distribution and geographic accessibility of prostate cancer clinical trials in the U.S.

Matthew D. Galsky, MD, discusses targeted therapy treatments for bladder cancer.

Matthew D. Galsky, MD, discusses the potential role of ipilimumab for the treatment of advanced bladder cancer.